MED
Dược Trung ương Mediplantex ·HNX ·2026Q1
▲▲ Improving positively
TTM · Applied to: EPS, ROE, ROA, Net Margin, Asset Turnover, Debt/Equity
What Is Changing
On a TTM 2026Q1 basis, MED is improving on both growth and profitability, painting a notably more positive picture versus the same period — profit is at an all-time high. When both scale and efficiency improve together, this is typically a sign of quality growth.
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 88.7 | 117.6 | 87.1 | 162.3 | 75.4 | 105.9 | 92.2 | 140.3 | 105.0 | 111.3 | 106.1 | 96.6 |
| Growth | -25% | +35% | -46% | +115% | -29% | +15% | -34% | +34% | -6% | +5% | +10% | — |
| Net Income | 5.9 | 6.1 | 3.9 | 5.2 | 2.2 | 2.9 | 3.5 | 4.9 | 3.8 | 4.1 | 3.4 | 3.3 |
| Net Margin | 6.68% | 5.22% | 4.49% | 3.22% | 2.89% | 2.74% | 3.78% | 3.50% | 3.65% | 3.71% | 3.22% | 3.44% |
Drivers of MED's profit
Net profit attributable to parent increased vs last year, mainly helped by higher gross profit. Supporting and offsetting drivers:
Net profit attributable to parent increased vs prior quarter, mainly helped by lower administrative expenses. Supporting and offsetting drivers:
Financial Highlights
Detailed analysis of each financial dimension
ROE = Profit Margin × Asset Turnover × Equity Multiplier
ROE rose from 4.1% to 6.3% — mainly driven by asset turnover, despite leverage moving in the opposite direction.
Is the profit sustainable?
Margins are improving and earnings quality is solid — a durable foundation for ROE.
What is driving the margin?
Net margin edged up to 4.65%, rising 1.4pp. Core operating signals are improving as Gross margin rose 1.7pp are enough to offset pressure from SG&A / Revenue rose 0.0pp (with lingering pressure from Net financial result / Revenue fell 0.2pp).
The improvement comes from core operations — this is a high-quality margin expansion.
Profitability trend
TTM YoY · 2025Q1 -> 2026Q1
Is capital being used efficiently?
Capital is being used more efficiently — ROIC rose and cash cycle shortened to 81.9 days.
Is capital being deployed efficiently?
ROIC expanded to 5.76%, rising 2.0pp. That translates to 5.76 in after-tax operating profit for every 100 units of operating capital. Both NOPAT margin rose 1.2pp and capital turnover rose 0.16x, with invested capital holding roughly steady — capital-return quality improved from both sides.
NOPAT margin led the improvement, but the ROIC level has not yet cleared typical cost of capital — margin needs to hold in coming periods rather than being a one-period rebound.
CAPITAL EFFICIENCY TREND
TTM YoY · 2025Q1 -> 2026Q1
Balance Sheet
ROIC is improving — the asset structure below shows how capital is being allocated. Capital structure is conservative with low leverage — liabilities at 0.38x equity, net debt at 0.06x equity.
Inventory ended the period at 93.2bn, roughly 20.4% of total assets.
Over the last 12 months, working capital absorbed 3.8bn of cash, mainly because of lower payables. Part of that drag was offset by lower receivables and lower inventories.
Working Capital Drivers
TTM YoY · 2025Q1 -> 2026Q1
Working Capital Efficiency
Working capital is being managed more efficiently, supporting overall capital efficiency. Cash conversion cycle improved by 33.4 days versus the same period last year. The main moves came from DIO fell 19.5 days, DSO fell 32.2 days, and DPO fell 18.3 days.
Improvement comes mainly from faster receivables collection — reflects the quality of receivables management.
Working Capital Efficiency
TTM YoY · 2025Q1 -> 2026Q1
Is financial risk significant?
Check leverage, liquidity, and cash-flow conversion.
Leverage & Liquidity
Leverage looks fairly comfortable, with net debt / equity at 0.06x and interest coverage at 5.49x.
At present, short-term debt accounts for 100.0% of total debt, cash equals 61.0% of debt, and total debt stands at 50.4bn.
Watchpoints
Short-term debt accounts for 100.0% of total debt, raising near-term refinancing needs.
Leverage and liquidity trend
TTM YoY · 2025Q1 -> 2026Q1
Cash Flow
Operating cash flow reached -5.4bn in 2025, against investing cash flow of -4.0bn.
Post-investment cash flow was negative +9.3bn. Financing cash flow was negative +8.9bn.
CFO / net income was 0.23x.
Track how much investment can be funded internally from operating cash flow.
Cash capex or FCF data is incomplete, so the cash-conversion view is only partial.
Cash Conversion
TTM Cash Conversion · 2025Q1 -> 2026Q1
Investment Takeaway
The business is entering a broader improvement phase — not just stronger earnings but better operating quality as well. Margin, ROIC, and cash flow all improving shows the business is growing in a cleaner and more efficient way than before. Notably, the improvement trend has been confirmed across multiple cycles, from margin to capital efficiency and cash generation. Even so, cash generation still needs confirmation remains the area to verify in upcoming periods.
Improvement: operating efficiency is getting better, with trailing-12M net margin at 4.65% after expanding 1.4pp versus the same period last year.
Watchpoint: Cash generation still needs confirmation.
Statement Data
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
|
Net Revenue
|
366.8 | 443.1 | 402.7 | 401.1 | 344.0 |
|
Cost of Goods Sold
|
281.0 | 350.6 | 319.7 | 322.6 | 0.0 |
|
Gross Profit
|
85.8 | 92.6 | 83.1 | 78.4 | 68.1 |
|
Financial Expenses
|
3.7 | 5.9 | 6.7 | 7.5 | -5.5 |
|
Selling Expenses
|
4.7 | 8.0 | 12.7 | 14.4 | -16.0 |
|
General and Administrative Expenses
|
58.6 | 62.4 | 56.2 | 54.9 | -43.2 |
|
Operating Profit
|
20.1 | 18.5 | 15.3 | 7.4 | 8.2 |
|
Profit Before Tax
|
20.7 | 19.4 | 14.9 | 8.2 | 5.5 |
|
Net Income
|
15.8 | 15.2 | 11.7 | 6.0 | 3.7 |
|
Profit Attributable to Parent
|
15.8 | 15.2 | 11.7 | 6.0 | 3.7 |
|
Earnings per Share
|
1,276.00 | 1,229.00 | 946.00 | 554.00 | 581.00 |
Explore Other Stocks In The Same Sector
DHG, DVN, IMP, DBD, DTP, TRA, DMC, DP3, OPC, NDC, DAN, PMC, VDP, DHT, FIT, DHD, AGP, DVM, CNC, PBC, LDP, DPH, VMD, NDP, HDP, DCL, PPP, VET, MTP, MKV, DHN, DBT, DTG, DPP, BIO, VNY, DBM, MKP, TW3, DTH, NTF, BCP, UPH, SPM, DP2, VXP
Need support? If you need support with content lookup or want to provide feedback about content on the website, please contact us below.